ArticleDrug design, development and therapy2025
Integrative Metabolomics and Ionomics Identify Organ-Specific Responses Associated with Cisplatin Treatment in Mice.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Agitation, Alzheimer's disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin is a widely used chemotherapeutic agent effective against various malignant tumors. However, its clinical application is limited by severe toxic side effects on multiple vital organs. Understanding the systemic metabolic and elemental alterations associated with cisplatin is essential for developing strategies to mitigate its toxicity. Methods: An integrative metabolomics and ionomics approach was employed to investigate organ-specific responses to cisplatin treatment in mice. Gas chromatography-mass spectrometry (GC-MS) and inductively coupled plasma-mass spectrometry (ICP-MS) were used to analyze metabolic and elemental changes in multiple organs, including the heart, liver, spleen, lungs, kidneys, cortex, hippocampus, brown adipose tissue, and blood. Histopathological evaluation was also performed to complement biochemical analyses. Results: Multivariate statistical analysis indicated that cisplatin was accompanied by significant changes in the levels of several key metabolites, including amino acids, fatty acids, and tricarboxylic acid cycle intermediates. A total of 9 metabolic pathways were implicated, particularly those involved in amino acid biosynthesis, energy metabolism, and redox regulation. In parallel, notable variations in metal ion concentrations, such as Ag, Na, Ca, Zn, Cu, Mg and Fe, were observed across organs. These changes may be linked to alterations in enzyme activity and antioxidant functions. Conclusion: This study provides a comprehensive overview of metabolic and elemental disturbances in vital organs correlated with cisplatin exposure. The findings suggest that modulation of specific metabolites and trace elements may help reduce cisplatin toxicity. The integrative omics approach offers novel insights into the pathways potentially underlying chemotherapy-induced side effects and highlights possible therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.